Jd. Jonkmandevries et al., PHARMACEUTICAL DEVELOPMENT OF A PARENTERAL LYOPHILIZED FORMULATION OFTHE NOVEL INDOLOQUINONE ANTITUMOR AGENT E09, Cancer chemotherapy and pharmacology, 34(5), 1994, pp. 416-422
The aim of this study was to design a stable parenteral dosing form of
the investigational cytotoxic drug, encoded EO9. EO9 exhibits poor aq
ueous solubility and stability characteristics. Freeze-drying was sele
cted as the manufacturing process. Differential scanning calorimetry s
tudies were conducted to determine the freeze-drying cycle parameters.
A stable lyophilized formulation of EO9 was developed. The prototype,
containing 8.0 mg EO9 and 200 mg lactose/vial, was found to be the op
timal formulation in terms of solubility, length of the freeze-drying
cycle, stability, and dosing requirements for phase I clinical trials.
Quality control of the freeze-dried formulation showed that the manuf
acturing process does not change the integrity of EO9. Shelf-life stud
ies demonstrated that the formulation remains stable for at least 1 ye
ar when stored at +4 degrees C in a dark environment.